Relmada Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Relmada Therapeutics

10/11/2022 22:01

* Relmada Therapeutics Inc  RLMD.OQ  reported a quarterly
adjusted
loss of $1.31​​ per share for the quarter ended in September.
The mean expectation of seven analysts for the quarter was for a
loss of $1.45 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Relmada Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.31​.
    * The mean earnings estimate of analysts had fallen by
about 4.9%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Relmada Therapeutics Inc shares had fallen by 84.4% this
quarter and lost 74.4% so far this year.
    * The company reported a quarterly loss of $39.42 million.
    * Wall Street's median 12-month price target for Relmada
Therapeutics Inc is $9.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 10:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -1.45          -1.31          Beat
 Jun. 30 2022      -1.27          -1.33          Missed
 Mar. 31 2022      -1.27          -1.40          Missed
 Dec. 31 2021      -1.83          -1.80          Beat